...
机译:DPYD C.1129-5923 C> G / HAPB3与阶段结肠癌患者的5-氟尿嘧啶化疗的严重毒性之间的关联:NCCTG N0147(联盟)
Mayo Clin Dept Mol Pharmacol &
Expt Therapeut MPET Ctr Canc 200 1st St SW Rochester MN 55905;
Mayo Clin Alliance Stat &
Data Ctr Rochester MN USA;
Mayo Clin Div Med Oncol Rochester MN USA;
Mayo Clin Alliance Stat &
Data Ctr Rochester MN USA;
Mayo Clin Div Med Oncol Rochester MN USA;
Univ Hawaii Ctr Canc Dept Surg Canc Prevent &
Control Program Honolulu HI 96822 USA;
Mayo Clin Div Med Oncol Rochester MN USA;
Univ Chicago Med Ctr GI Oncol Dept Med Chicago IL USA;
Vanderbilt Ingram Canc Ctr Div Hematol Oncol Nashville TN USA;
Univ British Columbia British Columbia Canc Agcy Div Med Oncol Dept Med Vancouver BC V5Z 1M9;
Surg Oncol Associates South Texas San Antonio TX USA;
Lehigh Valley Hlth Network John &
Dorthy Morgan Canc Ctr Dept Hematol Oncol Allentown PA USA;
Wayne State Univ Barbara Ann Karmanos Canc Inst Dept Oncol Detroit MI USA;
Ohio State Univ Med Ctr Div Med Oncol Dept Hematol Oncol Columbus OH 43210 USA;
Mayo Clin Dept Mol Pharmacol &
Expt Therapeut MPET Ctr Canc 200 1st St SW Rochester MN 55905;
5-fluorouracil; toxicity; pharmacogenetics; colon cancer; polymorphism; dihydropyrimidine dehydrogenase;
机译:DPYD c.1129-5923 C> G / hapB3与III期结肠癌患者对基于5-氟尿嘧啶的化学治疗的严重毒性之间的关联:NCCTG N0147(联盟)
机译:III阶段结肠癌患者的身体活动和结果:III期试验NCCTG N0147(联盟)的相关分析
机译:大肠癌家族史及其对III期结肠癌切除患者生存的影响:NCCTG试验N0147(联盟)的结果
机译:不应常规向患有阶段结肠癌的患者常规的辅助化学疗法,表明微卫星不稳定性
机译:具有阶段I,II或III肺,结肠或直肠癌的退伍军人治疗发起的医院和患者特征
机译:DPYD c.1129-5923 C G / hapB3与III期结肠癌患者对基于5-氟尿嘧啶的化学治疗的严重毒性之间的关联:NCCTG N0147(联盟)
机译:患有切除阶段III结肠癌的患者的Folfiri比较有或没有西妥昔单抗; NCCTG(联盟)互动试验N0147